An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

Zhuolong Zhou,Kevin Van der Jeught,Yuanzhang Fang,Tao Yu,Yujing Li,Zheng Ao,Sheng Liu,Lu Zhang,Yang Yang,Haniyeh Eyvani,Mary L. Cox,Xiyu Wang,Xiaoming He,Guang Ji,Bryan P. Schneider,Feng Guo,Jun Wan,Xinna Zhang,Xiongbin Lu
DOI: https://doi.org/10.1038/s41551-021-00805-x
IF: 28.1
2021-11-01
Nature Biomedical Engineering
Abstract:In breast cancer, genetic heterogeneity, the lack of actionable targets and immune evasion all contribute to the limited clinical response rates to immune checkpoint blockade therapy. Here, we report a high-throughput screen based on the functional interaction of mouse- or patient-derived breast tumour organoids and tumour-specific cytotoxic T cells for the identification of epigenetic inhibitors that promote antigen presentation and potentiate T-cell-mediated cytotoxicity. We show that the epigenetic inhibitors GSK-LSD1, CUDC-101 and BML-210, identified by the screen, display antitumour activities in orthotopic mammary tumours in mice, that they upregulate antigen presentation mediated by the major histocompatibility complex class I on breast tumour cells and that treatment with BML-210 substantially sensitized breast tumours to the inhibitor of the checkpoint programmed death-1. Standardized measurements of tumour-cell killing activity facilitated by tumour-organoid–T-cell screens may help with the identification of candidate immunotherapeutics for a range of cancers.
engineering, biomedical
What problem does this paper attempt to address?